As the population of the United States ages, the rates of dementia are also likely to increase. Clinicians will, therefore, likely be asked to evaluate and treat an escalating number of patients experiencing a decline in multiple domains of cognitive function, which is the hallmark of neurocognitive disorders. It is also probable that clinicians will be confronted with management dilemmas related to the myriad of psychological and behavioral problems that often occur as a consequence of the neurocognitive impairment. In fact, these behavioral and psychological issues might be the initial symptoms that lead the patient to present to the clinician. Dementia has multiple potential etiologies, and a careful diagnostic assessment is imperative to best characterize the specific type of dementia impacting the patient. This is important, as knowing the type of dementia helps the clinician choose the most effective treatment. Potential treatments should be interdisciplinary in scope, patient/family-centered, and may include both nonpharmacologic and pharmacologic treatments.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Publishing, 2013.
2.
PrinceMBryceRAlbaneseE. The global prevalence of dementia: a systematic review and meta-analysis. Alzheimers Dement2013; 9: 63–75.
3.
NasreddineZSPhillipsNABédirianV. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc2005; 53: 695–699.
4.
RossettiHCLacritzLHCullumCM. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology2011; 77: 1272–1275.
5.
American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc2012; 60: 616–631.
6.
DuránCEAzermaiMVander SticheleRH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol2013; 69: 1485–1496.
7.
APA Work Group on Alzheimer'™s Disease and other Dementias, Rabins PV, Blacker D, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. Am J Psychiatry 2007; 164: 5–56.
8.
KnopmanDSBoeveBFPetersenRC. Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clin Proc2003; 78: 1290–1308.
9.
WoodsBAguirreESpectorAE. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev2012; 2: CD005562.
10.
AisenPSSchneiderLSSanoM. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA2008; 300: 1774–1783.
11.
Freund-LeviYEriksdotter-JönhagenMCederholmT. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol2006; 63: 1402–1408.
12.
DyskenMWSanoMAsthanaS. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA2014; 311: 33–44.
13.
MillerERPastor-BarriusoRDalalD. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med2005; 142: 37–46.
14.
RainaPSantaguidaPIsmailaA. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med2008; 148: 379–397.
15.
HowardRMcShaneRLindesayJ. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med2012; 366: 893–903.
16.
McShane R, Areosa Sastre A and Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006: Art no. CD003154.
17.
FarrimondLERobertsEMcShaneR. Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMJ Open2012; 2. PII: e000917. DOI: 10.1136/bmjopen-2012-000917.
18.
MendezMFLauterbachECSampsonSM. An evidence-based review of the psychopathology of frontotemporal dementia: a report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci2008; 20: 130–149.
19.
SleegersKCrutsMVan BroeckhovenC. Molecular pathways of frontotemporal lobar degeneration. Annu Rev Neurosci2010; 33: 71–88.
20.
BeiHuRossLNeuhausJ. Off-label medication use in frontotemporal dementia. Am J Alzheimers Dis Other Demen2010; 25: 128–133.
RobinsonKM. Rehabilitation applications in caring for patients with Pick’s disease and frontotemporal dementias. Neurology2001; 56: S56–S58.
23.
MendezMF. Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci2009; 24: 168–178.
24.
MorettiRTorrePAntonelloRM. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol2003; 49: 13–19.
25.
LebertFStekkeWHasenbroekxC. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord2004; 17: 355–359.
26.
MendezMFShapiraJSMcMurtrayA. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry2007; 15: 84–87.
27.
BoxerALKnopmanDSKauferDI. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol2013; 12: 149–156.
28.
KerteszAMorlogDLightM. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord2008; 25: 178–185.
29.
FujishiroHFermanTJBoeveBF. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol2008; 67: 649–656.
30.
MoriEIkedaMKosakaK. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol2012; 72: 41–52.
31.
WangHFYuJTTangSW. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry2015; 86: 135–143.
32.
KurlanRCummingsJRamanR. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology2007; 68: 1356–1363.
GagnonJFPostumaRBMontplaisirJ. Update on the pharmacology of REM sleep behavior disorder. Neurology2006; 67: 742–747.
35.
GorelickPBScuteriABlackSE. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke2011; 42: 2672–2713.
36.
StottDJMacIntoshGLoweGD. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr2005; 82: 1320–1326.
37.
PriceJFStewartMCDearyIJ. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ2008; 337: a1198.
38.
KavirajanHSchneiderLS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol2007; 6: 782–792.
39.
FrenchDDLaMantiaMALivinLR. Healthy Aging Brain Center improved care coordination and produced net savings. Health Aff (Millwood)2014; 33: 613–618.
40.
UnützerJKatonWCallahanCM. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA2002; 288: 2836–2845.
